Leading integrated drug discovery partner, Sygnature Discovery (“Sygnature”) has announced its acquisition of one of North America’s largest discovery Contract Research Organisations, Canada-based NuChem Sciences. This acquisition cements Sygnature as one of the world’s largest players in integrated drug discovery phase solutions and advances their vision to become the global market leader.
News
Check out a roundup of news, updates and highlights from ValiRx this month, including their attendance at ON Helix 2023: ValiRx News Roundup - August 2023
"ValiRx and Inaphaea teams attend On Helix
AMSBIO announce a new range of pre-made Nano-Lantern lentivirus products that utilize a proprietary lentiviral vector system to enable highly sensitive and precise in vivo luminescence imaging.
This cutting-edge Nano-Lantern lentivirus technology, which consists of an enhanced Renilla-Luciferase connected to an Orange Fluorescent protein (OFP), represents a significant improvement over previous methods and is poised to revolutionize many in vivo imaging applications.
Patients could benefit from bespoke cancer-fighting treatments with fewer side effects thanks to a new partnership between a biotech company and a UK university.
The University of Leicester has joined forces with Cambridge-based Isogenica to develop new immunotherapies – a process where the patient’s immune system is helped to fight cancer – which will be tested on a ‘virtual patient’.
Alexion, AstraZeneca’s rare disease subsidiary, is acquiring a portfolio of preclinical gene therapy programs from Pfizer. The deal will bring a number of novel adeno-associated virus (AAV) capsids to Alexion and help build on AstraZeneca’s capabilities in genomic medicine.
Cambridge, United Kingdom, 26th July 2023 / Domainex Ltd., a leading, integrated medicines research services partner and recent recipient of the King’s Award for Enterprise in International Trade, announces the purchase of its third, multi-channel Malvern Panalytical WAVEdelta system, powered by Creoptix technology. Simultaneously, Domainex announces the expansion of its biophysical suite of technologies through the purchase of a Malvern Panalytical PEAQ-ITC instrument with MicroCal technology.
San Diego, CA - BioMed Realty, a leading provider of real estate solutions to the life science and technology industries, announced that Charlie Piscitello has joined the company as Chief People Officer.
In this role, Mr. Piscitello will lead the Company’s human resource related functions, including talent management, culture, and diversity, equity, and inclusion, reporting to Tim Schoen, CEO of BioMed Realty, and will be based in BioMed Realty’s San Diego headquarters.